These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32493964)

  • 1. Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
    Asanuma K; Nakamura T; Hayashi A; Okamoto T; Iino T; Asanuma Y; Hagi T; Kita K; Nakamura K; Sudo A
    Sci Rep; 2020 Jun; 10(1):9077. PubMed ID: 32493964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
    Orth MF; Buecklein VL; Kampmann E; Subklewe M; Noessner E; Cidre-Aranaz F; Romero-Pérez L; Wehweck FS; Lindner L; Issels R; Kirchner T; Altendorf-Hofmann A; Grünewald TGP; Knösel T
    Cancer Immunol Immunother; 2020 Jul; 69(7):1353-1362. PubMed ID: 32222780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
    Kim C; Kim EK; Jung H; Chon HJ; Han JW; Shin KH; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim SH; Kim HS
    BMC Cancer; 2016 Jul; 16():434. PubMed ID: 27393385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.
    Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
    Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
    BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
    Kelany M; Barth TF; Salem D; Shakweer MM
    Pathol Oncol Res; 2021; 27():1609804. PubMed ID: 34276259
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
    Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
    Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
    Hashimoto K; Nishimura S; Ito T; Akagi M
    Eur J Histochem; 2021 Jul; 65(3):. PubMed ID: 34218652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.
    Kim JR; Moon YJ; Kwon KS; Bae JS; Wagle S; Kim KM; Park HS; Lee H; Moon WS; Chung MJ; Kang MJ; Jang KY
    PLoS One; 2013; 8(12):e82870. PubMed ID: 24349382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
    PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
    Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
    Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
    Park H; Bang JH; Nam AR; Eun Park J; Hua Jin M; Bang YJ; Oh DY
    Sci Rep; 2019 Jul; 9(1):11131. PubMed ID: 31366979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.